CureVac

Today we spent time at the Chardan 8th Annual Genetic Medicines Conference, where Our Chief Business Officer Thaminda Ramanayake participated in an insightful fireside chat, discussing CureVac’s vision, near-term focus and the role of #mRNA in elevating the genetic medicines landscape.     It was a great opportunity to hear from both investors and other innovators on a range of important topics driving medical innovation forward, and we were proud to be able to offer our unique perspective.   #mRNA #GeneticMedicine #Oncology #Chardan #Biotech

Our Chief Business Officer Thaminda Ramanayake will be heading to New York City next week to participate in a fireside chat during the Chardan 8th Annual Genetic Medicines Conference.   We greatly look forward to connecting with investors and peer companies as we all come together to discuss the future of genetic medicine and its many possibilities.   #mRNA #HealthcareInnovation #Chardan #Biotech

We're excited to announce that our colleague Roland Böttger, Senior Scientist at CureVac, will be speaking at the 3rd Lipid Nanoparticle Development Summit, taking place in Berlin September 24-26. This event brings together leading experts in the field to discuss the latest advancements in lipid nanoparticle technology—a crucial area in drug delivery and vaccine development.   Roland will be sharing his insights tomorrow in a seminar titled: An mRNA-LNP Vaccine Platform Tailoring the Immunogenicity Profile from Prophylactic to Therapeutic Applications, Reducing Reactogenicity and Extending Shelf-Life Stability.   Looking forward to connecting with everyone at the summit!   #LipidNanoparticles #HealthcareInnovation #DrugDelivery

We are pleased to announce that our CSO, Dr. Myriam Mendila has been invited to speak at the very first Hamburg Science Summit on September 19, 2024. Hosted by the Koerber Stiftung and Hamburg's Ministry of Science, this prestigious event will gather leading figures from science, politics, business, and NGOs to discuss critical topics impacting Europe’s future. This year's summit will center on Europe's technological sovereignty, addressing how Europe can maintain competitiveness in vital areas such as artificial intelligence, energy storage, and medical technologies. Myriam will be part of a distinguished panel titled "The Future of Health: Medical Breakthroughs Made in Europe," alongside Maria Blasco from the Spanish National Cancer Center and Iordanis Arzimanoglou from the European Innovation Council. This one-hour discussion will delve into the future of breakthrough innovation in health and medicine in Europe. Find out more about this event: https://lnkd.in/dE3NhK3d #Science #hamburgsciencesummit #healthcare

Today, CureVac joins the global community in recognizing World Patient Safety Day 🌎 This important day, established by the World Health Organization (WHO) in 2019, aims to raise awareness and drive actions to improve the safety of patients worldwide.   Every year, a new theme is selected for this global awareness day – this year’s theme is “improving diagnosis for patient safety”. An incorrect diagnosis, even minor, can unfortunately be a major roadblock to someone receiving the care they need.   But there are many critical elements at play when it comes to patient safety that go beyond an initial diagnosis journey.   At CureVac, patient safety is at the heart of everything we do. And we are committed to working to develop innovative mRNA therapies with the highest safety standards to ensure the well-being of patients across the globe.   #WorldPatientSafetyDay #PatientSafety #CureVac #Healthcare #Innovation #mRNA   For more information on World Patient Safety Day, visit: https://lnkd.in/gjS5EjV

🏃♂️ Reflecting on the Tübinger Erbe Lauf 2024! 🏃♀️ We were delighted to have sponsored our employees' participation in this fantastic event, supporting our community and celebrating the spirit of sportsmanship and togetherness. It was great to see so many participants come together for a day full of energy, smiles, and incredible achievements - and all of it for a good cause. A special shoutout to our RNA people who took part in the run—they had a blast! Looking forward to next year already! 🏅 #TübingerErbeLauf #CommunitySupport #TeamRNA #ProudSponsor #RunningForFun

Yesterday was an exciting day for us as the first in-human data from our Phase 1 study of our cancer vaccine candidate CVGBM was presented by the brilliant Professor Ghazaleh Tabatabai at the ESMO - European Society for Medical Oncology Congress 2024. Expanding on that excitement, our team was very pleased to see that #ESMODailyReporter selected our data as a highlight of Day 1 of the conference.   You can check out the full article here: https://bit.ly/47taIWZ   #ESMO2024 #mRNA

Today, we are thrilled to share positive data from our Phase 1 cancer vaccine study in glioblastoma, presented today at ESMO - European Society for Medical Oncology Congress 2024! This is a significant milestone for CureVac. It marks the first clinical data ever presented on the CVGBM program. But importantly, the strength of the data – notably, the ability of CVGBM to generate new immune responses in patients – underscores the potential of our second-generation mRNA backbone in the larger fight against cancer. We look forward to building upon this encouraging data with the next phase of this trial. You can find more information in our press release here: https://lnkd.in/eTQzKTah   #ESMO2024 #CancerVaccines #mRNA #Oncology #Cancer 

It’s unbelievable that we’re just one day out from the start of ESMO - European Society for Medical Oncology Congress 2024!   We thought we might drop a reminder that our team will be presenting at ESMO the very first clinical data from the Phase 1 study of our mRNA-based cancer vaccine candidate CVGBM.   You can check out more details below on CureVac’s participation at this conference.   #mRNA #CancerVaccines #ESMO2024

Today, GSK announced positive Phase 2 headline data from the seasonal influenza mRNA program; this was a program developed through our previous collaboration with GSK and which was fully licensed to them under the terms of our licensing agreement announced back in July.   The seasonal influenza vaccine candidate is based on our second-generation mRNA backbone, and, according to GSK, the Phase 2 headline data demonstrated positive immune responses to A and B strains compared to current standard of care and suggests an acceptable safety and reactogenicity profile. We are very excited to see this data further validate the power of our second-generation mRNA backbone.   Additionally, GSK indicated that the Phase 2 results support advancing the seasonal influenza program into Phase 3.   Please find our press here with more information: https://lnkd.in/evQvCva4   #SeasonalInfluenza #mRNAVaccine #mRNA #GSK